Data analytics firm Verisk said on Wednesday it will buy AccuLynx, which makes software for roofing contractors, for $2.35 ...

The abrupt exit of the former CBER director, who quickly made his mark at the agency with several high-profile and ...

But while many analysts presented a bullish case for the company's turnaround, not all investors are sold on Niccol and his "Back to Starbucks" strategy. The comeback is taking longer than originally ...

Fintel reports that on July 29, 2025, William Blair downgraded their outlook for NeoGenomics (NasdaqCM:NEO) from Outperform ...

Boeing reported second quarter earnings on Tuesday that topped expectations and stemmed the tide of cash burn that has ...

PTC Therapeutics secures FDA approval for Sephience in PKU, launching August with analysts projecting strong revenue and ...

Exelixis Q2 revenue missed estimates, but strong Cabometyx sales lifted earnings. STELLAR trial delays and strategy shifts ...

Sarepta Therapeutics shares snapped a three-day losing streak on Tuesday, as analysts said resumption of U.S. shipments for ...

Sarepta Therapeutics shares jumped over 36% on Tuesday after the company said it had received FDA approval to restart ...

William Blair cheers Tesla-Samsung chip deal but keeps TSLA at Hold, citing auto margin woes and valuation concerns.

The U.S. Food and Drug Administration (FDA) announced on Friday, after market close, that it is investigating the death of an ...

In its own communique issued shortly after the FDA’s, Sarepta elaborated on the situation and confirmed a Roche statement to ...